Cover Image
Market Research Report
Product code 
363122

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021

Published: | Global Markets Direct | 202 Pages | Delivery time: 1-2 business days

Price

Back to Top
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021
Published: September 30, 2021
Global Markets Direct
Content info: 202 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

According to the recently published report 'Complement C5 - Drugs In Development, 2021'; Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 43 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

The report 'Complement C5 - Drugs In Development, 2021' outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 13, 3, 5, 1, 16 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Central Nervous System, Infectious Disease, Ophthalmology, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic's Syndrome), Coronavirus Disease 2019 (COVID-19) Pneumonia, Autoimmune Disorders, Chronic Inflammation, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Kidney Disease (Nephropathy), Lupus Nephritis, Age Related Macular Degeneration, Bullous Pemphigoid, Dermatomyositis, Geographic Atrophy, Guillain-Barre Syndrome, Hidradenitis Suppurativa, IgA Nephropathy (Berger's Disease), Thrombotic Microangiopathy, Unspecified, Uveitis, Acute Lung Injury, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Antiphospholipid Syndrome, Atopic Keratoconjunctivitis, Bacterial Sepsis, Cardiovascular Inflammation, Choroidal Neovascularization, Community Acquired Pneumonia, Fibrosis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hematuria, Hemorrhagic Shock, Intermediate Uveitis, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Lung Disease, Microscopic Polyangiitis (MPA), Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Posterior Uveitis, Primary Progressive Multiple Sclerosis (PPMS), Pyoderma Gangrenosum, Rheumatoid Arthritis, Sepsis, Septic Shock, Sickle Cell Disease With Vaso-Occlusive Crisis, Squamous Cell Carcinoma, Subarachnoid Hemorrhage, Sudoriferous (Sweat) Gland Disorders, Trauma, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome) and Unspecified Ophthalmological Disorders.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2967TDB

Table of Contents

Table of Contents

  • Introduction
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Indications, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Products under Development by Companies, 2021 (Contd..5)
  • Products under Development by Companies, 2021 (Contd..6)
  • Products under Development by Companies, 2021 (Contd..7)
  • Products under Development by Companies, 2021 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Adienne Pharma & Biotech SA, 2021
  • Pipeline by Akari Therapeutics Plc, 2021
  • Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Pipeline by Alnylam Pharmaceuticals Inc, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by Aptarion Biotech AG, 2021
  • Pipeline by Biocad, 2021
  • Pipeline by Biosion Inc, 2021
  • Pipeline by CANbridge Life Sciences Ltd, 2021
  • Pipeline by Chugai Pharmaceutical Co Ltd, 2021
  • Pipeline by Generium, 2021
  • Pipeline by ImmunAbs Inc, 2021
  • Pipeline by InflaRx NV, 2021
  • Pipeline by ISU ABXIS Co Ltd, 2021
  • Pipeline by IVERIC bio Inc, 2021
  • Pipeline by Navigen Inc, 2021
  • Pipeline by Novartis AG, 2021
  • Pipeline by NovelMed Therapeutics Inc, 2021
  • Pipeline by Prestige BioPharma Ltd, 2021
  • Pipeline by Ra Pharmaceuticals Inc, 2021
  • Pipeline by Rallybio Corp, 2021
  • Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Pipeline by Samsung Bioepis Co Ltd, 2021
  • Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2021
  • Pipeline by Staidson BioPharma Inc, 2021
  • Pipeline by Tasly Biopharmaceuticals Co Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Dormant Products, 2021 (Contd..2)
  • Dormant Products, 2021 (Contd..3)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021